E2F1 and hepatocellular carcinoma: Drug sensitivity results directly indicated that HCC cells with high expression of CENPA, E2F1, FOXM1, HMGA1, HMGB2, MYBL2 and TCF19 were less sensitive to trametinib (Fig. 10B).